Global Medical Affairs Strategy and Evidence Generation—Geographic Atrophy

Provide scientific guidance to the Board of Directors and the leadership of the Foundation, including guidance on grant requests from academic partners in the area of rare and ultrarare disease, lysosomal storage disorders, neuroinflammation, and gene therapyhttp://www.ml4.org/ML4 is a genetic disease causing mental retardation, retinal degeneration, and limited lifespan. The mission of the Foundation is to fund, promote, and support medical research dedicated to developing treatments and a cure for ML4.

Clinical Development Study Lead for nAMD and DME Gene Therapy Trials/Extension StudiesWork closely with scientific and medical advisors and cross functional partners to better elucidate and mitigate the immune response to gene therapyDevelop the Scientific Communication PlatformEvidence Generation and Scientific Communication Strategy

Worked in the areas of rare disease gene therapy, neurodevelopmental and neurodegenerative diseaseGene Therapy for Rett Syndrome and Friedreich's AtaxiaDeveloped the Early Program Medical Affairs Strategy for Rett Syndrome and Friedreich's AtaxiaDeveloped intelligence plan for Early Program Medical Affairs for Rett Syndrome and Friedreich's AtaxiaServed as the Medical Affairs Lead on the Global Program Teams for Rett Syndrome and Friedreich's Ataxia

Launched Zolgensma in Spinal Muscular AtrophyContributed to the development of the US Medical Plan and the Integrated Product Strategy for ZolgensmaDeveloped training and resources for the US field team in support of the Zolgensma launch as part of the US field leadership team

As a member of the Dermatology and Rheumatology Medical Leadership Team, I am responsible for the development and execution of the external tactics ad strategy in support of the overall medical strategyLed Rheumatology (Cosentyx) Field Medical Tactics Development in Psoriatic ArthritisLed Rheumatology (Cosentyx) Field Medical Tactics Development in Ankylosing SpondylitisLed Dermatology (Cosentyx) Field Medical Tactics Development for in PsoriasisLed Rheumatology (ILARIS) Field Medical Tactics Development in SJIA and Periodic Fever SyndromesDeveloped and led novel workshops to enhance the ability of MSL teams to communicate medical and scientific information in a compelling mannerDeveloped medical tactics for key competitor launches in dermatology and rheumatology that have enabled continued growth of secukinumab market share Launched ILARIS in expanded periodic fever indications

Dermatology and RheumatologyLaunched ILARIS in SJIALaunched Xolair for CIU in DermatologyLaunched Cosentyx in PsoriasisLaunched Cosentyx in Psoriatic ArthritisLaunched Cosentyx in Ankylosing SpondylitisRe-established field medical affairs in CA for Novartis in Dermatology and RheumatologyNational coordinator for the Dermatology and Rheumatology external research program

• Diabetes• Immunology• Regenerative Medicine

Regenerative Medicine Applications for Adult and Placental Mesenchymal Stem Cells• Led a cross-functional research and development program defining the regenerative potential of placental, cord blood, bone marrow, and adipose MSC that led to the establishment of two veterinary stem cell clinics• Led business development efforts for partnering with regenerative medicine and biomaterials companies • Developed biomarker profiles for stem cells from multiple sources• Developed cGMP manufacturing processes for processing, expanding and banking bone marrow, umbilical cord blood, umbilical cord matrix, and adipose MSC expansion• Managed all biologics related verification and validation studies in support of product research and development• Managed the operation of stem cell laboratories and conduct of all stem cell related research

Gene Networks Regulating Osteoblast Differentiation• Managed a research program on stem cells and regenerative medicine• Used microarray analysis to evaluate BMP and Wnt induced signaling networks in human mesenchymal stem cells (hMSC) undergoing adipogenic and osteogenic differentiation• Developed novel micro RNA-based retroviral vectors to knock-down osteoblast specific gene expression• Developed in vivo models of bone formation• Supervised and directed all laboratory patent applications

Immunotherapy for Cancer• Managed a project to redirect the immune response of T-cells to melanoma• Studied T-cell trafficking to lymphatic tissue.• Developed dendritic cell based vaccines for use in mouse tumor models.Gene Therapy for Cancer• Managed a gene therapy project to develop next generation viral vectors for human applications• Designed and constructed retroviral vectors encoding a melanoma antigen specific T-cell receptor.• Designed retroviral vectors encoding chimeric antigen receptors (CARs) directed against HER2 to redirect the immune response to breast cancer• Developed protocols for highly efficient retroviral transduction of primary human T-lymphocytes and CD34+ hematopoietic cells. Bone Marrow Transplant for Systemic Sclerosis• Isolated human CD34+ cells for autologous stem cell transplants in systemic sclerosis patients• Supervised collection of human hematopoietic stem cells under GMP conditionsSickle Cell Disease • Studied induction of the gamma globin promoter by short chain carboxylic acids and histone deacetylase inhibitors.• Employed luciferase reporter systems to analyze levels of gene induction. General Lab Duties • Established and maintained transgenic mouse colony• Maintained lab equipment, supplies, and freezers• Supervised fellows and undergraduate students